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ABSTRACT
Summary: We present Vacceed, a highly configurable and scalable
framework designed to automate the process of high-throughput in
silico vaccine candidate discovery for eukaryotic pathogens. Given
thousands of protein sequences from the target pathogen as input,
the main output is a ranked list of protein candidates determined by a
set of machine learning algorithms. Vacceed has the potential to save
time and money by reducing the number of false candidates allocated
for laboratory validation. Vacceed, if required, can also predict protein
sequences from the pathogen’s genome.
Availability and implementation: Vacceed is tested on Linux and can
be freely downloaded from https://github.com/sgoodswe/vacceed/re
leases (includes a worked example with sample data). Vacceed User
Guide can be obtained from https://github.com/sgoodswe/vacceed.
Contact: John.Ellis@uts.edu.au
Supplementary information: Supplementary data are available at
Bioinformatics online.
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1 INTRODUCTION
Several subunit vaccines against prokaryotic pathogens have
been identified (Ariel et al., 2002; Montigiani et al., 2002; Ross
et al., 2001) using reverse vaccinology (Rappuoli, 2000). Vaxign
(He et al., 2010) and NERVE (Vivona et al., 2006) are examples
of vaccine discovery tools for prokaryotes, but there is currently
no equivalent tool for eukaryotes. Freely available bioinfor-
matics tools and an unprecedented volume of –omics data now
present an opportunity for in silico vaccine discovery for eukary-
otic pathogens. A general approach is to use several tools to
predict and gather evidence for protein characteristics. From
this potential evidence, the researcher makes an informed deci-
sion as to a protein’s vaccine candidacy suitability. Determining
which tools are appropriate, as well as how to use them, presents
the first of many challenges. A further challenge, especially to a
researcher with limited programming ability, is to extract and
gather the pertinent evidence distributed within large-scale out-
puts. The subsequent and more imposing challenge is that the
evidence is mainly in different formats, contradicting and in-
accurate. Poor evidence reliability arises because some of the
input data to the tools (e.g. protein sequences and training
data) are inaccurate or missing. Moreover, tools used to predict
protein characteristics are, in general, inaccurate.
Vaccine candidates identified in silico can only be validated in
a laboratory. Validation should provide feedback to inform and
improve vaccine candidacy decision making. The repetitive
nature for this ideal in silico approach is in need of automation.
Furthermore, an automated process must accommodate an ever-
increasing choice of new or improved prediction programs that
inevitably replace existing ones.
We have developed Vacceed to address the challenges raised
here i.e. to provide a flexible, automated process to predict
worthy vaccine candidates from large volumes of superfluous,
disseminated and noisy data. Vacceed is the collective name for
a framework of linked bioinformatics programs, Perl scripts, R
functions and Linux shell scripts. A previous published study
provided guidance in development (Goodswen et al., 2013b).
2 DISTINCTIVE FEATURES
A detailed description of all aspects of Vacceed is provided in a
comprehensive user guide provided as Supplementary
Information. The focus of this article is to introduce Vacceed
via a selection of distinctive features.
The Vacceed framework is built around the concept of linked
resources (see Fig. 1). Each resource, in this context, is built from
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Fig. 1. Vacceed framework. A set hierarchal structure exists for the exe-
cution of all Vacceed scripts e.g. startup ! master script ! resource
script! subordinate script (only three resources are shown to maintain
clarity)
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a central Linux shell script encapsulating all programs needed to
perform specific but related tasks. Typical tasks include pre-
dicting a particular protein characteristic as well as pre- and
post-validation. A resource can be executed as an independent
modular unit. This flexible design allows for scalability and easy
maintenance. Any prediction program can be integrated within
an existing or new resource if it meets the following criteria: runs
in a Linux environment, has high-throughput capability, is ap-
plicable to eukaryotes, can be trained or has trained data specific
to target pathogen and provides consistent text output. From a
user’s perspective, all the work involved in the complexity of
linking tasks and resources into a seamless continuous pipeline
has already been resolved in Vacceed. The only time a user must
be concerned with the contents of a resource is when adding a
new one. There is a template resource script and generic Perl
scripts to ease this process.
Core to Vacceed are user-definable configuration files
(see Fig. 2). These files are in effect the user’s interface to con-
figuring each resource, if desired, and consequently controlling
the outcome of the entire pipeline. For example, by altering
names in a list, the user can determine the resources to be run
and their order. The expectation is to have one configuration file
for each target pathogen. The command-line syntax to invoke
Vacceed is ‘perl startup xx’, where xx determines the appropriate
configuration file. Specifying a code allows for multiple instances
of Vacceed to process different species or resource combinations.
No other user input is needed. An e-mail with attached log file is
sent on successful completion or immediately following an error.
The framework is organized into two major parts referred
henceforth as part A—build proteome, and part B—run pipeline
(see Fig. 3). Table 1 lists the programs currently integrated in
each part. A starting prerequisite for part B is a file containing
amino acid sequences for proteins from the target eukaryotic
pathogen i.e. the proteome. Known protein sequences for
many pathogens can be downloaded from public databases.
Part A is used, only if required, to predict novel protein se-
quences and/or collect evidence to support the existence of
known proteins. Part A resources typically predict genes, which
is one among multiple tasks within linked resources involved in
building the proteome. Examples of other tasks are validating
gene start and end sequences (e.g. ATG, TAA, TAG or TGA),
Table 1. Programs currently integrated in Vacceed
Name Function URL (last viewed May 2014)
Part A—Build proteome
Augustus Ab initio gene predictor http://bioinf.uni-greifswald.de/augustus
GlimmerHMM Ab initio gene predictor http://ccb.jhu.edu/software/glimmerhmm
BLAT Aligns expressed sequence tags (ESTs) to DNA http://genome.ucsc.edu/FAQ/FAQblat.html
GMAP Aligns expressed sequence tags (ESTs) to DNA http://research-pub.gene.com/gmap
N-Scan Ab initio gene predictor supported by genome comparison http://mblab.wustl.edu/software.html
BLASTN Finds regions of similarity between nucleotide sequences http://www.ncbi.nlm.nih.gov
BLASTP Finds regions of similarity between protein sequences http://www.ncbi.nlm.nih.gov
Part B—Run pipeline (vaccine candidate discovery)
WoLf PSORT Protein subcellular localization prediction http://wolfpsort.seq.cbrc.jp
SignalP Predicts presence and location of signal peptide cleavage sites http://www.cbs.dtu.dk/services/SignalP
TargetP Protein subcellular localization prediction http://www.cbs.dtu.dk/services/TargetP
Phobius Combined transmembrane topology and signal peptide predictor http://phobius.binf.ku.dk/instructions.html
TMHMM Prediction of transmembrane helices in proteins http://www.cbs.dtu.dk/services/TMHMM
MHC I-binding Peptide binding to MHC class I molecules http://tools.immuneepitope.org/mhci/download
MHC II-binding Peptide binding to MHC class II molecules http://tools.immuneepitope.org/mhcii/download
Fig. 2. Extract of a Vacceed configuration file defined by a header-key
format (only one resource, WoLF PSORT, is shown for brevity) Fig. 3. Schematic of data flow in Vacceed
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predicting exon locations relative to gene start, converting pre-
dictions to amino acid sequences and homology searching.
Part B resources predict protein characteristics. One resource
called ‘Evidence’, however, parses output files and collates
relevant protein characteristics (referred henceforth as an evi-
dence profile). A typical profile is a mixture of data types
corresponding to an accuracy measure or score for the pre-
dicted characteristic (see Fig. 4). A crucial feature of the re-
source is a set of supervised machine learning algorithms for
binary classification executed via Rscript. The ensemble of
classifiers constitutes the heart of Vacceed’s decision making.
The main output is a ranked vaccine candidate list of all pro-
teins in the target pathogen based on an average probability of
individual classifier predictions (see Fig. 4). Machine learning
algorithms are the key to overcoming the challenge that an
unknown percentage of evidence is questionable in each
profile.
Resources encapsulate, for the most part, a large number of
independent computation-intensive tasks. Vacceed takes advan-
tage of multi-core processors. Part A processes one chromosome
per CPU in parallel. Chromosomes are queued if there are more
chromosomes than CPUs. The user, however, can specify the
number of chromosomes to process in parallel. Part B internally
splits the proteins by the number of CPUs and processes each
subset in parallel. Alternatively, the user can specify the split
value.
Proof of concept: There is no program yet to evaluate in silico
vaccine candidates in a host–vaccine interaction. The best interim
option is to validate the in silico process by predicting candidates
using experimentally validated proteins with known immunogen-
icity characteristics i.e. compare predicted with expected to de-
termine sensitivity and specificity of the process. Using a mixed
dataset of 140 published proteins observed to induce or not
induce immune responses, we demonstrated in an earlier study
(Goodswen et al., 2013a) Vacceed’s decision making potential by
effectively distinguishing expected true from expected false vac-
cine candidates, with an average sensitivity and specificity of 0.97
and 0.98, respectively.
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Fig. 4. Examples of evidence profiles and a ranked vaccine candidate list
(only four proteins out of potentially thousands constituting the target
pathogen are shown for brevity)
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